A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2011
03/23/2011	EP2296663A1 Combinations comprising methotrexate and dhodh inhibitors
03/23/2011	EP2296662A1 Inhibitors of plk
03/23/2011	EP2296661A1 Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment
03/23/2011	EP2296660A1 Anti-tumour compositions and methods
03/23/2011	EP2296659A2 Drug combinations comprising a dgat inhibitor and a ppar-agonist
03/23/2011	EP2296658A2 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
03/23/2011	EP2296657A1 Method of treating anxious major depressive disorder
03/23/2011	EP2296656A1 Dihydrotetrabenanzine for the treatment of anxiety
03/23/2011	EP2296655A1 Quinolynylmethylimidizoles as therapeutic agents
03/23/2011	EP2296654A1 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
03/23/2011	EP2296653A1 Compounds and methods for treating inflammatory and fibrotic disorders
03/23/2011	EP2296652A1 Topical regional neuro-affective therapy
03/23/2011	EP2296651A1 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
03/23/2011	EP2296650A1 Immunomodulation by iap inhibitors
03/23/2011	EP2296649A1 Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
03/23/2011	EP2296648A1 Naphthylmethylimidizoles for the treatment of stress urinary incontinence
03/23/2011	EP2296647A2 Pai-1 expression and activity inhibitors for the treatment of ocular disorders
03/23/2011	EP2296646A2 Novel treatments
03/23/2011	EP2296645A2 Combination antitumor therapy
03/23/2011	EP2296644A1 Combination compositions comprising antimycotic agents and statins and the use thereof
03/23/2011	EP2296643A1 Nutritional composition for improving the mammalian immune system
03/23/2011	EP2296642A1 Compositions comprising amino acids, with pro-angiogenic activity
03/23/2011	EP2296641A1 Diaryl urea for treating heart failure
03/23/2011	EP2296640A1 Methods for preventing the development of retinopathy by the oral administration of nnr ligands
03/23/2011	EP2296639A1 Emollient composition for the preventive treatment of atopic dermatitis
03/23/2011	EP2296638A2 Identification of a molecular signature for antipsychotics and serms
03/23/2011	EP2296637A1 Chitosan-containing protective composition
03/23/2011	EP2296636A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
03/23/2011	EP2296635A2 Artificial oxygen carriers and use thereof
03/23/2011	EP2296634A1 Process for manufacture of a medicament with granulation and pan coating
03/23/2011	EP2296633A2 The use of solid carrier particles to improve the processability of a pharmaceutical agent
03/23/2011	EP2296631A1 Method for manufacturing medicinal compounds containing dabigatran
03/23/2011	EP2296627A2 Micelles for intracellular delivery of therapeutic agents
03/23/2011	EP2296625A1 Pharmaceutical formulation of ketorolac for intranasal administration
03/23/2011	EP2296621A1 Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
03/23/2011	EP2296597A1 Polyamine enhanced formulations for triptan compound iontophoresis
03/23/2011	EP2296475A1 Triazolopyridine jak inhibitor compounds and methods
03/23/2011	EP2296474A1 Novel substituted indoles
03/23/2011	EP2296472A1 Compounds for rho kinase inhibition and for improving learning and memory
03/23/2011	EP2296471A1 Muscarinic agonists as cognitive enhancers
03/23/2011	EP2296470A2 Compositions and methods for inhibiting gastric acid secretion
03/23/2011	EP2296469A1 Kappa opioid receptor ligands
03/23/2011	EP2296467A2 Methods to control qoi-resistant fungal pathogens
03/23/2011	EP2296464A1 Salts and polymorphs of a tetracycline compound
03/23/2011	EP2296462A1 Rasagiline for parkinson's disease modification
03/23/2011	EP2229358B1 Indoles and their therapeutic use
03/23/2011	EP2205604B1 {[5-(phenyl)-6-phenylpyrrolo[2,1-f][2,1,4]triazin-4-yl]amino}carboxylic acid derivatives and related compounds as prostacyclin (pgi2) ip receptor activators for treating cardiovascular disorders
03/23/2011	EP2203440B1 Inhibitors of the interaction between mdm2 and p53
03/23/2011	EP2200991B1 Antibacterial agents
03/23/2011	EP2195314B1 Disubstituted alkyl-8-azabicyclo [3.2.1.]octane compounds as mu opioid receptor antagonists
03/23/2011	EP2195311B1 Pyridine derivatives as s1p1/edg1 receptor modulators
03/23/2011	EP2185567B1 Substituted bicyclolactam compounds
03/23/2011	EP2144909B1 [2,6]naphthyridines useful as protein kinase inhibitors
03/23/2011	EP2136785B1 Process for dosing self-emulsifying drug delivery systems
03/23/2011	EP2118111B1 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer
03/23/2011	EP2111387B1 New method for preparing unsaturated fatty hydroxy-acids
03/23/2011	EP2109608B1 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
03/23/2011	EP2102214B1 4, 5, 6, 7-tetrahydro-thieno [3, 2-c] pyridine derivatives as h3 modulators
03/23/2011	EP2086643B1 Compounds which potentiate ampa receptor and uses thereof in medicine
03/23/2011	EP2076260B1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
03/23/2011	EP2049467B1 Therapeutic amides and related compounds
03/23/2011	EP2023918B1 Cyclosporins for the treatment and prevention of ocular disorders
03/23/2011	EP2012763B1 Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
03/23/2011	EP1983990B1 A3 adenosine receptor allosteric modulators
03/23/2011	EP1965801B1 Combination of azd2171 and pemetrexed
03/23/2011	EP1942891B1 Novel combination of drugs as antidepressant
03/23/2011	EP1934208B1 Novel polymorphous form of 5-chloro-n-({ (5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
03/23/2011	EP1896417B1 Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
03/23/2011	EP1888054B1 Antimicrobial composition
03/23/2011	EP1881960B1 Novel specific caspase-10 inhibitors
03/23/2011	EP1851228B1 Pyrimidothiophene compounds having hsp90 inhibitory activity
03/23/2011	EP1843764B1 Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
03/23/2011	EP1838665B1 Mutilin derivatives and their use as pharmaceutical
03/23/2011	EP1772145B1 Method of effectively using medicine and method concerning prevention of side effect
03/23/2011	EP1694842B1 Rna amidates and thioamidates for rnai
03/23/2011	EP1670464B1 Topical compositions comprising telmesteine for treating dermatological disorders
03/23/2011	EP1656127B1 Compounds for the treatment of metabolic disorders
03/23/2011	EP1650218B1 The artificial cpg single strand deoxidation oligonucleotide and its antiviral uses
03/23/2011	EP1578353B1 4-hydroxypiperidine derivatives useful as antimycobacterial agents
03/23/2011	EP1545519B1 Combination therapy for hyperproliferative diseases
03/23/2011	EP1515741B1 Use of collagen hydrolysate to lower the viscosity of a composition comprising guar gum
03/23/2011	EP1463529B9 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
03/23/2011	EP1448205B1 Combinations for the treatment of immunoinflammatory disorders
03/23/2011	EP1432669B1 4-(c2-6 alkoxy)-substituted chalcones as therapeutic agents
03/23/2011	EP1353647B1 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
03/23/2011	EP1330444B1 Nitrogenous heterocyclic compounds and process for making them
03/23/2011	EP1278748B1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
03/23/2011	EP1140836B1 Amide compounds
03/23/2011	EP1087960B1 Macrocyclic analogs and methods of their use and preparation
03/23/2011	CN1990489B Use of bohnenkraut ethers compounds and compositions thereof
03/23/2011	CN1956965B Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high CB1/CB2 receptor subtype selectivity
03/23/2011	CN1951372B Solid oral dosage forms comprising valsartan and HCTZ
03/23/2011	CN1942436B Lysine based compounds
03/23/2011	CN1939413B Compound douricien medicinal composition
03/23/2011	CN1931216B Medicine composition of safflower and rhodiola root
03/23/2011	CN1929824B Soft gelatin capsule comprising omega-3-polyunsaturated fatty acid
03/23/2011	CN1923228B Pharmaceutical composition comprising notoginseng extract, Danshen extract and ligustrazine
03/23/2011	CN1919243B Traditional medicine composition for treating cardiovascular and cerebrovascular diseases
03/23/2011	CN1895365B Oral liquid for treating fowl upper disease and its preparation
03/23/2011	CN1847236B 7,8-dihydroxy-2-oxo-2H-benzopyran derivative and its synthesis process and medicinal use

1 ... 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 ... 7860